ストックスクリーナーアプリを入手
129.26
1.18%
1.51
プレマーケット:
129.30
0.04
+0.03%
前日終値:
$127.75
開ける：
$130.33
24時間の取引高:
5.90M
Relative Volume:
0.88
時価総額：
$160.44B
収益：
$29.45B
当期純損益:
$8.51B
株価収益率:
19.06
EPS:
6.7823
ネットキャッシュフロー:
$9.46B
1週間 パフォーマンス:
-3.02%
1か月 パフォーマンス:
-3.72%
6か月 パフォーマンス:
+9.65%
1年 パフォーマンス:
+21.55%
1日の値動き範囲:
$128.34
$130.47
1週間の範囲:
$127.64
$134.68
52週間の値動き範囲:
$95.30
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
129.26 | 160.44B | 29.45B | 8.51B | 9.46B | 6.7823 |
LLY
Lilly Eli Co
|
874.00 | 780.79B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
227.79 | 548.34B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
197.69 | 349.67B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
186.68 | 289.51B | 58.80B | 10.24B | 8.98B | 3.2788 |
NVS
Novartis Ag Adr
|
145.50 | 277.63B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Daniel O'Day (GILD) files Form 144 to sell 10,000 performance shares - Stock Titan
Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Gilead Sciences (GILD) Closes $7.8B Arcellx Buyout — What Investors Need to Know - Blockonomi
Gilead Sciences (GILD) Stock Lands $7.8B Arcellx Deal — Is This the Buy Opportunity? - CoinCentral
Gilead Sciences, Inc. completed the acquisition of 77.2% stake in Arcellx, Inc. from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others. - marketscreener.com
Gilead Sciences Crosses Critical Breakout Level. The Stock Can Gain 35% From Here. - Barron's
Gilead Sciences completes acquisition of Arcellx ahead of potential commercial launch of Anito-cel - marketscreener.com
Gilead Completes $7.8 Billion Acquisition of Arcellx - Contract Pharma
Gilead Sciences Finalizes $7.8 Billion Acquisition of Arcellx - marketscreener.com
Gilead Sciences (GILD) Completes Acquisition of Arcellx, Inc. - GuruFocus
Recent Arcellx deal leaves Gilead Sciences stock consolidating amid persistent oversold signals - Traders Union
Gilead Sciences Completes $7.8 Billion Acquisition of Arcellx, Securing Full Control of CAR T Therapy Anito-cel - citybiz
Gilead Sciences Completes $7.8 Billion Acquisition of Arcellx to Accelerate Launch of Anito-cel CAR T Therapy for Multiple Myeloma 1 - Minichart
Gilead Sciences Completes Acquisition of Arcellx and Anito-cel - TipRanks
Gilead fully acquires Arcellx (NASDAQ: ACLX) as tender offer and merger close - Stock Titan
Gilead completes $7.8 billion acquisition of Arcellx - Investing.com
Gilead Sciences reports new GTPase KRAS G12D inhibitors and degraders - BioWorld News
Gilead completes $7.8 billion acquisition of Arcellx By Investing.com - Investing.com Canada
Gilead (NASDAQ: GILD) closes Arcellx deal, gains full control of anito-cel - Stock Titan
Gilead Sciences (ACLX) to close merger; 77.2% tendered, $115 cash plus CVR - Stock Titan
Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel - Business Wire
Mitsubishi UFJ Trust & Banking Corp Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
M&T Bank Corp Sells 147,548 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Stanford symposium appearance sees Gilead Sciences stock drop 2.03% - Traders Union
Gilead Sciences Inc. stock underperforms Monday when compared to competitors - MarketWatch
Gilead Sciences (GILD) Builds Defensive Moat With HIV Franchise Ahead of May 7 Earnings - AlphaStreet
Pictet Asset Management Holding SA Sells 326,886 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
State of Michigan Retirement System Sells 10,800 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Sanctuary Advisors LLC Has $27.19 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Obtains Regulatory Approval for Arcellx Acquisition - HarianBasis.co
Gilead Sciences (GILD) Set to Acquire Arcellx - Insider Monkey
A Look At Kymera Therapeutics (KYMR) Valuation After Fast Track News And Gilead Collaboration Progress - Yahoo Finance
Gilead Sciences nears $2B deal for Ouro MedicinesFT - MSN
Gilead Sciences Inc. (GILD): Growing Popularity as Defensive Stock - Yahoo Finance
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Vanguard Group Inc. Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Concurrent Investment Advisors LLC Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Axecap Investments LLC Has $3.43 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
AEGON ASSET MANAGEMENT UK Plc Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit - MSN
Impax Asset Management Group plc Acquires 19,894 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Polaris Capital Management LLC - MarketBeat
Gilead Sciences Inc (NASDAQ:GILD): A Balanced Dividend Play with Strong Financial Health and Profitability - ChartMill
Calamos Advisors LLC Sells 9,121 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Gilead’s Arcus Pullback and Idvynso HIV Challenge Might Change The Case For Investing In GILD - Yahoo Finance
NBC Securities Inc. Acquires 10,296 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD is Kerusso Capital Management LLC's 6th Largest Position - MarketBeat
Teacher Retirement System of Texas Sells 33,061 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Apr 15 '26 |
Sale |
140.96 |
3,000 |
422,880 |
176,191 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Apr 15 '26 |
Sale |
140.96 |
3,000 |
422,880 |
128,779 |
1.16%
0.91%
大文字化:
|
ボリューム (24 時間):